Lau, Gary YF

Research Interests:

Viral immunity, Immune correlates of protection, Vaccine designs, Adjuvant technologies, Qualitative analysis of immune responses, Pre-existing immunity on vaccine efficacy.

Selected Publications:

Chen, G. L.*, Y.-F. Lau*, E. W. Lamirande, A. W. McCall, and K. Subbarao. 2011. Seasonal influenza infection and live vaccine prime for a response to the 2009 pandemic H1N1 vaccine. Proc Natl Acad Sci USA 108:1140-5.  * equal first authors

Lau, Y.-F., C. Santos, F. J. Torres-Vélez, and K. Subbarao. 2011. The magnitude of local immunity in the lungs of mice induced by live attenuated influenza vaccines is determined by local viral replication and induction of cytokines. J Virol 85:76-85.

Lau, Y.-F., L.-H. Tang, A. W. McCall, E.-E. Ooi, and K. Subbarao. 2010. An Adjuvant for the Induction of Potent, Protective Humoral Responses to an H5N1 Influenza Virus Vaccine with Antigen-Sparing Effect in Mice. J Virol 84:8639-49.

Chen, J.*, Y. F. Lau*, E. W. Lamirande, C. D. Paddock, J. H. Bartlett, S. R. Zaki, and K. Subbarao. 2010. Cellular immune responses to severe acute respiratory syndrome coronavirus (SARS-CoV) infection in senescent BALB/c mice: CD4+ T cells are important in control of SARS-CoV infection. J Virol 84:1289-301. *equal first authors

Lau, Y.-F., L.-H. Tang, E.-E. Ooi, and K. Subbarao. 2010. Activation of the innate immune system provides broad-spectrum protection against influenza A viruses with pandemic potential in mice. Virology 406:80-7

Lau, Y., L. Tang, and E. Ooi. 2009. A TLR3 ligand that exhibits potent inhibition of influenza virus replication and has strong adjuvant activity has the potential for dual applications in an influenza pandemic. Vaccine 27:1354-64.

Lau, Y., G. Deliyannis, W. Zeng, A. Mansell, D. Jackson, and L. Brown. 2006. Lipid-containing mimetics of natural triggers of innate immunity as CTL-inducing influenza vaccines. Int Immunol 18:1801-13.

Jackson, D., Y. Lau, T. Le, A. Suhrbier, G. Deliyannis, C. Cheers, C. Smith, W. Zeng, and L. Brown. 2004. A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses. Proc Natl Acad Sci U S A 101:15440-5.